istock-508859346_walterbilotta-1

walterbilotta/ iStockphoto.com

10 November 2017Big Pharma

LSIPR 50 2017: Sean Dennehey—Steering the ship

2016 was a tumultuous year. Not only did the UK vote to leave the EU, but the UK Intellectual Property Office (IPO) lost its CEO and two experienced directors.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Teva fights for re-listing of inhaler patents at US appeals court

White & Case hires experienced litigator from A&O Shearman

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

Sanofi subsidiary fends off $450m trade secrets case

Teva faces $500m fine for antitrust breaches over MS drug

Pfizer infringed haemophilia therapy patent, says court